Tegafur-Uracil (Cat No.:I043648) is a combination chemotherapy agent used primarily in the treatment of colorectal cancer. It combines tegafur, a prodrug of 5-fluorouracil (5-FU), with uracil, which inhibits the degradation of tegafur, allowing for prolonged 5-FU activity. This combination enhances the efficacy of 5-FU by improving its pharmacokinetics and reducing side effects. UFT is typically used in adjuvant or palliative treatment for colorectal cancer and is also being explored for other cancers. Its ability to target rapidly dividing cancer cells makes it a valuable chemotherapeutic option.